Definitions

• This invention relates generally to biocompatible implants and related devices, and more particularly to a thermal packaging unit for heating biocompatible implants.
• biocompatible implants are made from a wide variety of materials including natural human bone, various nontoxic biocompatible metals, and many different types of plastics including polymer materials.
• One method which has been suggested to deform such a biocompatible implant is to heat the biocompatible implant to a temperature where the biocompatible implant becomes malleable. Once the biocompatible implant becomes malleable, the biocompatible implant is deformed to the desired shape and then allowed to cool.
• the biocompatible implant is placed in a hot water bath for a sufficient length of time so as to cause the biocompatible implant to become malleable. After the biocompatible implant has been heated to such a temperature, the biocompatible implant is removed from the hot water bath and then is deformed.
• electrical energy is delivered to an electrode so as to cause the electrode to generate thermal energy.
• the biocompatible implant is then brought into a position adjacent to the electrode so as to cause the temperature of the biocompatible implant to rise. After the temperature of the biocompatible implant rises to such a temperature so as to become malleable, the biocompatible implant is deformed to the desired shape and allowed to cool.
• An advantage of the present invention is to provide a thermal packaging unit for a biocompatible implant which includes a self-contained heating mechanism.
• a related object of the present invention is to provide a thermal packaging unit for a biocompatible implant which is able to heat the biocompatible implant without the use of an external source of energy.
• a further advantage of the present invention is to provide a thermal packaging unit for a biocompatible implant which is able to heat the biocompatible implant to a temperature where the biocompatible implant may be deformed.
• a related object of the present invention is to provide a thermal packaging unit for a biocompatible implant which is able to heat the biocompatible implant to a temperature substantially that of its glass transition temperature.
• Another advantage of the present invention is to provide a thermal packaging unit for a biocompatible implant which may be used to reheat the biocompatible implant.
• a further advantage of the present invention is to provide a thermal packaging unit for a biocompatible implant which reduces the complexity associated with enhancing the sterility of the biocompatible implant.
• Another advantage of the present invention is to provide a thermal packaging unit in which the sterility of the biocompatible implant can be maintained from when the biocompatible implant is manufactured to immediately before implantation.
• a further advantage of the present invention is to provide a thermal packaging unit for a biocompatible implant which is able to reduce the cost associated with sterilizing the biocompatible implant before implantation.
• the present invention in one form thereof, provides an apparatus for heating a biocompatible implant.
• the apparatus includes means for receiving the biocompatible implant as well as means for heating the biocompatible implant.
• the means for heating the biocompatible implant is self-contained and is disposed adjacent to the means for receiving the biocompatible implant.
• the invention in another form thereof, provides a method for heating a biocompatible implant.
• the method comprises the step of disposing the biocompatible implant in a heating device which includes means for receiving the biocompatible implant as well as means for delivering thermal energy to the biocompatible implant.
• the method further comprises the step of activating the heating device so as to cause the thermal energy to be delivered to the biocompatible implant.
• the method also includes the step of allowing the biocompatible implant to be heated to a temperature where the biocompatible implant becomes deformable.
• the method includes the step of removing the biocompatible implant from the heating device after the biocompatible implant becomes deformable.
• FIG. 1 is a cross-sectional view of a biocompatible implant according to the teachings of the preferred embodiment of the present invention shown in association with a hip joint prosthesis;
• FIG. 2 is an enlarged elevational view of a biocompatible implant shown in FIG. 2 according to the teachings of the preferred embodiment of the present invention
• FIG. 3 is a view of a biocompatible implant in accordance with a preferred embodiment of the present invention taken in the direction of line 3-3 in FIG. 2;
• FIG. 4 is a cross-sectional view of a thermal packaging unit used for heating the biocompatible implant shown in FIG. 2 according to the teaching of a preferred embodiment of the present invention
• FIG. 5 is an enlarged cross-sectional view of a bioresorbable implant according to the teachings of the preferred embodiment of the present invention shown as being disposed within a cavity formed within the intramedullary canal of a femur.
• FIG. 6 is a cross-sectional view of a thermal packaging unit used for heating the biocompatible implant shown in FIG. 2 according to the teaching of another preferred embodiment of the present invention
• FIG. 7 is a cross-sectional view of a thermal packaging unit used for heating the biocompatible implant shown in FIG. 2 according to the teaching of yet another preferred embodiment of the present invention
• FIG. 8 is an elevational view of a thermal packaging unit used for heating the biocompatible implant shown in FIG. 2 according to the teaching of yet another preferred embodiment of the present invention.
• FIG. 9 is a cross-sectional view of the thermal packaging unit shown in FIG. 8.
• FIG. 1 there is shown a biocompatible implant 10 which may be used with the preferred embodiments of the present invention.
• the biocompatible implant 10 is shown as being disposed within a cavity 12 formed in the intramedullary canal of a femur 14.
• a hip joint prosthesis generally designated by the numeral 16, is positioned within the cavity 12.
• the hip joint prosthesis 16 is shown to include a head component 18 for engaging an acetabular component 20 that is secured to the pelvis 22.
• the hip joint prosthesis 16 further includes a stem portion 24 that is inserted into the cavity 12 and that is used to secure the hip joint prosthesis 16 to the femur 14.
• the biocompatible implant 10 is positioned within the cavity 12 beyond the distal end of the stem portion 24 of the hip joint prosthesis 16. While the biocompatible implant 10 is depicted as being a bone plug, it will be appreciated that the biocompatible implant 10 may be any other type of biocompatible or bioresorbable implant exhibiting similar properties that is also deformable at a thermochemical state different from that existing within a body but is relatively rigid at a thermochemical state existing within a body.
• thermochemical state as used in describing the present invention is defined as a combination of thermal and chemical conditions resulting from exposure to certain thermal and chemical environments. Although one type of change in thermochemical state occurs by a change of temperature alone, changes in thermochemical state of a biocompatible implant of the present invention should be understood as not limited only to changes in temperature.
• the biocompatible implant 10 includes a main body 26 having a rounded lower end 28 and an upper end 30.
• the upper end 30 includes an open recess 32 that is defined by an annular wall 34 and is used to receive an insertion tool (not shown) .
• the annular wall 34 is shown to include a plurality of threads 36 that are disposed on the inner surface of the annular wall 34.
• the threads 36 are sized to receive a matching threaded end of the insertion tool that allows the biocompatible implant 10 to be removably secured to the insertion tool. It will be appreciated, however, that any other suitable means for allowing the biocompatible implant 10 to be inserted into the cavity 12 by an insertion tool may be used.
• the biocompatible implant 10 further includes an upper first flange 38 and a lower second flange 40 that extend radially from the main body 26.
• Both the first and second flanges 38 and 40 are planar and circular in nature, with the diameter of the first flange 38 being larger than the diameter of the second flange 40.
• the first and second flanges 38 and 40 are used for engaging the wall of the cavity 12 when biocompatible implant 10 is inserted into the cavity 12.
• the flanges 38 and 40 also enhance a seal for restricting the flow of bone cement from the portion of the cavity 12 above the biocompatible implant 10 to the portion of the cavity 12 directly below the biocompatible implant 10.
• the first flange 38 includes a plurality of concentric ridges 42 disposed on its lower surface while the second flange 40 also has a plurality of concentric ridges 44 disposed on its lower surface as shown in FIG. 3.
• the ridges 42 and 44 serve to enhance the positional stability of the biocompatible implant 10 within the cavity 12 by engaging the walls of the cavity 12 upon insertion therein of the biocompatible implant 10.
• the biocompatible implant 10 is formed from a bioresorbable material that is substantially rigid at body temperature but becomes pliable or deformable at temperature somewhat above body temperature.
• a bioresorbable material that is substantially rigid at body temperature but becomes pliable or deformable at temperature somewhat above body temperature.
• One such material is an 82:18 copolymer of polylactic acid and polyglycolic acid.
• the glass transition temperature of this material is between approximately 40° C and 60° C so that heating of the biocompatible implant 10 to a deformable temperature preferably 5-10° above the glass transition temperature allows the biocompatible implant 10 to be easily deformed as the biocompatible implant 10 is inserted into the cavity 12 in the manner described below. It should be understood that other suitable biocompatible materials may be used that have a glass transition temperature above body temperature.
• These materials include polymers, copolymers, fibers and films of polyglycolide, polylactide, polydioxanone, poly(glycolide-co-trimethylene carbonate) , poly(ethylene carbonate) , poly(iminocarbonates) , polycaprolactone, polyhydroxybutyrate, polyesters, poly(amino acids), poly(ester-amides) , poly(orthoesters) , poly(anhydrides) and cyanoacrylates and copolymers and blends thereof.
• Barrows, T.H A review of these materials as well known degradable synthetic implant materials is set forth in Barrows, T.H.
• the biocompatible implant 10 may be heated by a thermal packaging unit 50.
• the thermal packaging unit 50 is able to generate thermal energy that is transferred to the biocompatible implant 10 so as to cause the temperature of the biocompatible implant 10 to be substantially that of its glass transition temperature. Because the biocompatible implant 10 is deformable at this elevated temperature, the biocompatible implant 10 may be relatively easily inserted into the cavity 12 of the femur 14. It will also be noted from the following discussion that the thermal packaging unit 50 is self-contained in that the elements used for heating the biocompatible device 10 are located within the thermal packaging unit 50.
• thermal packaging unit 50 includes a first compartment 56 that defines a storage area 52 for receiving the biocompatible implant 10, and a second compartment 58 that is disposed within the first compartment 56.
• the first compartment 56 includes an inner wall 60 that is disposed adjacent to the storage area 52 and an external surface defined by an outer wall 62.
• the inner wall 60 and outer wall 62 act as a barrier to moisture, microbes or other contaminants which enhances a relatively sterile and relatively dry condition within the storage area 52 thereby minimizing degradation of the biocompatible implant 10 by exposure to the environment.
• the inner wall 60 is preferably made from a laminate including a linear low density film of 3 to 4 mils thickness, a high temperature adhesive layer, an aluminum foil layer, a second high temperature adhesive layer and a second linear low density film of 3 to 4 mils thickness, although other suitable materials may be used.
• the outer wall 62 is preferably made from a laminate including a linear low density film of 3 to 4 mils thickness, a high temperature adhesive layer, an aluminum foil layer, a second high temperature adhesive layer and an insulating layer, although other suitable materials may be used.
• the insulating layer may be made from any flexible insulating material well known to those skilled in the art and is used to retain the thermal energy generated within the first compartment 56.
• the insulating layer is a laminate including a 60 to 100 gauge biaxial oriented nylon sheet, a high temperature adhesive layer, a microfoam-blown polypropylene layer and a non- woven film, such as nylon.
• first compartment 56 may be separated into segments by means of a separating wall 66.
• the separating wall 66 can also be constructed to provide two second compartments 58 within thermal packaging unit 50 thereby making each half of thermal packaging unit 50 independently activated.
• the thermal packaging unit 50 also includes a top seal 68 that maintains a relatively moisture-free environment within the storage area 52.
• the top seal 68 is preferably resealable so as to allow the biocompatible implant 10 to be reinserted into the storage area 52. This may be necessary when the temperature of the biocompatible implant 10 cools to a temperature below its glass transition temperature before the insertion process can be attempted or successfully completed.
• the first compartment 56 is operable to contain calcium chloride while the second compartment 58 is operable to contain water.
• water from the second compartment 58 is able to combine with the calcium chloride in the first compartment 56 in an exothermic reaction.
• thermal energy is transferred from the first compartment 56 to the biocompatible implant 10 which causes the temperature of the biocompatible implant 10 to rise.
• the biocompatible implant 10 becomes increasingly deformable and may be easily inserted into the cavity 12.
• the biocompatible implant 10 cools to body temperature which is below the glass transition temperature of the biocompatible implant 10. When this occurs, the bioresorbable implant 10 becomes relatively rigid so as to resist further movement within the cavity 12.
• thermal packaging unit 50 The use of thermal packaging unit 50 will now be described in greater detail. Shortly before the biocompatible implant 10 is to be implanted, an insertion tool (not shown) is removably attached to the biocompatible implant 10 by threading the insertion tool onto the plurality of threads 36 that are disposed on the inner surface of the annular wall 34. The biocompatible implant 10 and the attached end of the insertion tool are then inserted into the thermal packaging unit 50. To enhance the heating operation, the top seal 68 is substantially closed around the insertion tool, which protrudes from the thermal packaging unit 50. Activation of thermal packaging unit 50 is then accomplished by gently squeezing thermal packaging unit 50 from its exterior so as to rupture second compartment 58.
• the thermal packaging unit 50 is capable of maintaining this elevated temperature of the storage area 52 for approximately 15 - 20 minutes so as to allow the biocompatible implant 10 to be reheated if necessary.
• the top seal 68 of the thermal packaging unit 50 is opened from around the insertion tool and the biocompatible implant 10 and the insertion tool are removed from the thermal packaging unit 50 and are inserted, with the rounded lower end 28 of the biocompatible implant 10 first, into the cavity 12.
• the first and second flanges 38 and 40 deform in a direction toward the open recess 32.
• the biocompatible implant 10 is forced into the cavity 12 to a position approximately 1 to 2 centimeters past the expected position of the distal end of the stem 24 of the hip joint prosthesis 16.
• the biocompatible implant 10 it is possible to reinsert the biocompatible implant 10 into the thermal packaging unit 50 for reheating should a delay occur before the biocompatible implant 10 can be inserted into the cavity 12.
• the biocompatible implant 10 cools to a temperature below its glass transition temperature thereby returning to a relatively rigid condition.
• the biocompatible implant 10 is secured in a substantially stationary position within cavity 12. After the biocompatible implant 10 is secured in this manner, the insertion tool is detached from the biocompatible implant 10 and is removed from the cavity 12.
• the biocompatible implant 10 may be placed within the thermal packaging unit 50 without being attached to the insertion tool.
• the top seal 68 can be substantially closed during the heating operation, and the insertion tool is attached to the biocompatible implant 10 immediately prior to the removal of the biocompatible implant 10 from the thermal packaging unit 50.
• the biocompatible implant 10 After the biocompatible implant 10 is properly secured within the cavity 12 and has cooled below its glass transition temperature, bone cement 72 is introduced into the cavity 12 and the stem portion 24 is thereafter inserted into the cavity 12.
• the action of inserting the stem portion 24 into the cavity 12 causes pressurization of the bone cement 72 within the cavity 12 which causes the bone cement 72 to interdigitate with the stem portion 24 and the wall of the cavity 12.
• the first and second flanges 38 and 40 of the biocompatible implant 10 restrict the flow of the bone cement 72 to a position below the biocompatible implant 10 within the cavity 12.
• the stem portion 24 becomes secured to the femur 14.
• the final position of biocompatible implant 10, the bone cement 72 and stem portion 24 within the cavity 12 of femur 14 is illustrated in FIG. 5.
• the biocompatible implant 10 is absorbed by natural functions within 1 to 1- 1/2 years. During and after this time, bone cells or a fibrous tissue may fill into the space previously occupied by the biocompatible implant 10 and the portion of the cavity 12 below the biocompatible implant 10.
• the thermal packaging unit 50 may contain only one rupturable compartment whose contents may be introduced to air, water or an external activating compound in order to activate the exothermic or thermodynamic reaction which heats the biocompatible implant 10.
• three or more compartments may be used that can include different reactants that may be located within the first compartment 56. In this case, simultaneous exothermic reactions can occur by simultaneous rupturing of all barriers separating the compartments.
• the first compartment 56 may have multiple storage compartments for multiple supplies of the same chemical reactants. Such an arrangement would make it possible for sequential rupturing of these compartments so as to allow the duration of the thermal energy generated by the thermal packaging unit 50 to increase.
• the thermal packaging unit 50 may take the form shown in FIGS. 6-9. In these alternative embodiments, similar features common to those shown in FIG. 4 are referenced by numerals that are 100, 200 and 300 greater than the corresponding numerals in FIG. 4. Each of these alternative embodiments of the thermal packaging unit 50 will be more fully described below.
• the thermal packaging unit 150 shown in FIG. 6 includes a first compartment 156 that defines a storage area 152 for receiving the biocompatible implant 10.
• the first compartment 156 includes an inner wall 160 that is disposed adjacent to the storage area 152 and an external surface defined by an outer wall 162.
• the inner wall 160 and outer wall 162 act as a microbial and moisture barrier which maintains a relatively sterile and relatively dry condition within the storage area 152 thereby minimizing degradation of the biocompatible implant 110 by exposure to the environment.
• the inner wall 160 is preferably made from a laminate including a linear low density film of 3 to 4 mils thickness, a high temperature adhesive layer, an aluminum foil layer, a second high temperature adhesive layer and a second linear low density film of 3 to 4 mils thickness, although other suitable materials may be used.
• the outer wall 162 is made in a preferred embodiment from a laminate including a linear low density film of 3 to 4 mils thickness, a high temperature adhesive layer, an aluminum foil layer, a second high temperature adhesive layer and an insulating layer, although other suitable materials may be used.
• the insulating layer may be made from any flexible insulating material well known to those skilled in the art and is used to retain the thermal energy generated within the first compartment 156. In one preferred embodiment, the insulating layer is a laminate including a 60 to 100 gauge biaxial oriented nylon sheet, a high temperature adhesive layer, a microfoam-blown polypropylene layer and a non-woven film, such as nylon.
• the thermal packaging unit 150 also includes a top seal 168 that maintains a relatively moisture-free environment within the storage area 152.
• the top seal 168 is preferably resealable so as to allow the biocompatible implant 110 to be reinserted into the storage area 152. This may be necessary when the temperature of the biocompatible implant 110 cools to a temperature below its glass transition temperature before the insertion process can be attempted or successfully completed.
• an injection port 174 Located on the exterior surface of the insulating layer 164 is an injection port 174 which is used to provide a resealable passageway from the external surface of the thermal packaging unit 150 to the first compartment 156.
• the injection port 174 is made from a compliant material that can be deformed and penetrated from an initial relatively sealed condition by an injection instrument such as a syringe or other suitable tool (not shown) . It is preferred that the injection port 174 be located exterior to the outer wall 162 so as not to disturb the initial interior microbial and moisture conditions within the storage area 152. The injection port 174 preferably returns to a relatively sealed condition following the withdrawal of the injection instrument from the injection port 174.
• the first compartment 156 is operable to contain calcium chloride which is reacted with water introduced by an injection instrument through the injection port 174. As water combines with the calcium chloride in the first compartment 156, an exothermic or thermodynamic chemical reaction occurs whereby thermal energy is generated within the first compartment 156 and is subsequently transferred from the first compartment 156 to the biocompatible implant 110 which causes the temperature of the biocompatible implant 110 to rise. It will be noted that the first compartment 156 may contain a different chemical reactant which may be combined with water or a suitable activating solvent other than water in the same manner described above to produce the desired exothermic or thermodynamic chemical reaction. It will also be noted that the first compartment
• thermal packaging unit 150 may be separated into segments by means of a separating wall, with a second injection port added for making each half of thermal packaging unit 150 independently activated.
• the thermal packaging unit 250 includes a first compartment 256 that defines a storage area 252 for receiving the biocompatible implant.
• the first compartment 256 is operable to contain a supercooled solution of sodium acetate and water.
• a metal activation disk 280 Disposed within the solution is a metal activation disk 280, which is operable to crystallize the solution of sodium acetate and water upon bending.
• the activation disk 280 is available from Prism Technologies and is operable to crystallize the sodium acetate and water solution in a manner described below.
• the first compartment 256 includes an inner wall 260 that is disposed adjacent to the storage area 252 and an external surface defined by an outer wall 262.
• the inner wall 260 and outer wall 262 act as a microbial and moisture barrier which maintains a relatively sterile and relatively dry condition within the storage area 252 thereby minimizing degradation of the biocompatible implant 210 by exposure to the environment.
• the inner wall 260 is made in a preferred embodiment from a laminate including a linear low density film of 3 to 4 mils thickness, a high temperature adhesive layer, a clear foil layer, a second high temperature adhesive layer and a second linear low density film of 3 to 4 mils thickness, although other suitable materials may be used.
• the outer wall 262 is made in a preferred embodiment from a laminate including a linear low density film of 3 to 4 mils thickness, a high temperature adhesive layer, a clear foil layer, a second high temperature adhesive layer and an insulating layer, although other suitable materials may be used.
• the insulating layer may be made from any flexible insulating material well known to those skilled in the art and is used to retain the thermal energy generated within the first compartment 256.
• the insulating layer is a laminate including a 60 to 100 gauge biaxial oriented nylon sheet, a high temperature adhesive layer, a microfoam-blown polypropylene layer and a non-woven film, such as nylon.
• the thermal packaging unit 250 also includes a top seal 268 that maintains a relatively moisture-free environment within the storage area 252.
• the top seal 268 is preferably resealable so as to allow the biocompatible implant 210 to be reinserted into the storage area 252. This may be necessary when the temperature of the biocompatible implant 210 cools to a temperature below its glass transition temperature before the insertion process can be attempted or successfully completed.
• the activation disk 280 is bent to initiate the reaction.
• Crystallization of the sodium acetate solution generates thermal energy within the first compartment 256 that is subsequently transferred from the first compartment 256 to the biocompatible implant 210, thereby causing the temperature of the biocompatible implant 210 to rise.
• the thermal packaging unit 250 can be reused for at least one additional use by boiling the thermal packaging unit 250 for a time sufficient to return the sodium acetate and water solution within the first compartment 256 to its previous state. Subsequent activation of the thermal packaging unit 250 is then accomplished in the same manner described above.
• first compartment 256 may contain a different chemical reactant which may be combined with a different suitable activating agent in the same manner described above to produce the desired exothermic or thermodynamic chemical reaction. It will also be noted that the first compartment 256 may be separated into segments by means of a separating wall, with a second activation disk added for making each half of thermal packaging unit 250 independently activated.
• the thermal packaging unit 350 is shown to include a first compartment 388 defined by the outer wall 390, which is partially separated into two portions by a perforated seal 382 extending through the central portion of the first compartment 388.
• an injection port 386 Disposed near the center top portion of the thermal packaging unit 350 is an injection port 386 for introducing an activation compound for initiating an exothermic or thermodynamic chemical reaction.
• the injection port 386 is preferably mounted upon the external surface of the outer wall 390 thereby providing a resealable passageway through the outer wall 390 from the external surface of the thermal packaging unit 350 to the first compartment 388.
• the injection port 386 is made from a compliant material that can be deformed and penetrated from an initial relatively sealed condition to accept an injection instrument such as a syringe or other suitable tool (not shown) .
• the injection port 386 preferably returns to a relatively sealed condition following the withdrawal of the injection instrument as before.
• the thermal packaging unit 350 further includes a pocket 384 disposed on one side for defining a storage space 392 for holding a biocompatible implant (not shown) and enhancing heat transfer and retention.
• the thermal packaging unit 350 is initially in a flat orientation. After the biocompatible implant to be heated is located within the pocket 384, the thermal packaging unit 350 is folded about the perforated seal 382 to substantially surround the biocompatible implant. This arrangement promotes convenience in inserting the biocompatible implant into and removing it from the thermal packaging unit 350.
• the thermal packaging unit 350 further includes an insulating layer 394 disposed upon the opposite surface of the thermal packaging unit 350 from the pocket 384.
• the insulating layer 394 may be made from any flexible insulating material well known to those skilled in the art and is used to retain the thermal energy generated within the first compartment 388 after the thermal packaging unit 350 is activated and is folded to surround the biocompatible bone plug being heated.
• the insulating layer 394 is a laminate including a 60 to 100 gauge biaxial oriented nylon sheet, a high temperature adhesive layer, a microfoam-blown polypropylene layer and a non-woven film, such as nylon.
• the first compartment 388 is operative to contain calcium chloride which is reacted with water introduced by an injection instrument through the injection port 386. As water combines with the calcium chloride in the first compartment 388, an exothermic or thermodynamic . chemical reaction occurs whereby thermal energy is generated within the first compartment 386. When the thermal packaging unit 350 is in a folded condition, this generated heat is transferred from the first compartment 388 to the biocompatible implant stored within the pocket 384 which causes the temperature of the biocompatible implant to rise. It will be noted that the first compartment may contain a different chemical reactant which may be combined with water or a suitable activating solvent other than water in the same manner described above to produce the desired exothermic or thermodynamic chemical reaction.
• the biocompatible implant can be removed from and reinserted into the pocket 384 as desired for satisfying the particular heating needs of an application. This may be necessary when the temperature of the biocompatible implant cools to a temperature below its glass transition temperature before the insertion process can be attempted or successfully completed. It should be noted that the folded condition of the thermal packaging unit 350 is more effective for developing a fully heated condition, as well as for maintaining a heated condition when a biocompatible implant is inserted into the pocket 384 and following removal of the implant, should a reheating become necessary.
• the implant used in the present invention may be of a biocompatible or bioresorbable material.
• the deformability characteristics of the implant may be altered by any change in thermochemical condition of the implant, such as exposure to one or more chemical compounds which react with the implant material so as to render it temporarily deformable prior to implantation.
• the thermal packaging unit may be supplied with an implant already positioned within the storage area or it may be supplied empty for insertion of an implant before activation.
• the thermal packaging unit may be used to enhance the sterility of the biocompatible implant from when the biocompatible implant is manufactured until immediately before the biocompatible implant is implanted.
• the use of the thermal packaging unit to enhance the sterility of the biocompatible implant reduces the costs which would otherwise be associated with enhancing the sterility of the biocompatible implant before implantation.
• the implant described herein may be used in connection with other types of surgical applications and with other types of tissue. The present invention will therefore be understood as susceptible to modification, alteration and variation by those skilled in the art without deviating from the scope and meaning of the following claims.

Landscapes

• Materials For Medical Uses (AREA)
• Prostheses (AREA)

Applications Claiming Priority (1)

Publications (2)

Family

ID=22237222

Family Applications (1)

Country Status (3)

Families Citing this family (2)

Citations (6)

• 1993
  • 1993-11-23 AU AU59834/94A patent/AU5983494A/en not_active Abandoned
  • 1993-11-23 JP JP7515566A patent/JPH09508816A/ja active Pending
  • 1993-11-23 EP EP94905916A patent/EP0731674A4/de not_active Withdrawn

Patent Citations (6)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events